Article Text
PDF
Abstract
Background In 2022, the number of refugees and asylum seekers (RAS) have reached an all-time high of 40.7 million globally. The surge in RAS, coupled with their limited access to healthcare (at their home and destination countries), has led to the risk of transmitting/acquiring sexually transmissible infections (STIs) and bloodborne viruses (BBVs). This situation threatens the health of RAS and poses a public health challenge to destination countries, potentially placing a burden on healthcare systems and resources. Healthcare recommendations for screening programmes for RAS vary between countries, leading to disparities in STI/BBV screening practices on arrival. These disparities can impact early detection and treatment of STIs/BBVs, increasing the risk of onward transmission and long-term negative sequelae. Therefore, this systematic review aims to investigate the prevalence and factors associated with STIs/BBVs among RAS.
Methods Six databases (ie, PubMed, Embase, Scopus, Cochrane Library, Web of Science and CINAHL) were searched for observational studies reporting STIs/BBVs prevalence and/or risk factors among RAS. The inverse variance heterogeneity model with double arcsine transformation was applied to prevalence meta-analysis of STIs/BBVs by region of origin of RAS. Narrative data synthesis was undertaken to summarise risk factors associated with STIs/BBVs.
Results A total of 21 studies (n=504 432 RAS) were included. Most studies were conducted among RAS arriving in Europe (n=14), followed by North America (n=5) and Australia (n=2). The highest prevalence of HIV (1.55%; 95% CI 0.53 to 3.04), syphilis (1.29%; 95% CI 0.59 to 2.24) and hepatitis B (6.50%; 95% CI 2.29 to 12.46) were observed among RAS from sub-Saharan Africa. The highest prevalence of hepatitis C was found in RAS from Southeast Asia (3.96%; 95% CI 2.74 to 5.38) and North Africa (3.59%; 95% CI 1.33 to 6.79). The highest prevalence of chlamydia was reported among RAS from the Middle East (1.48%; 95% CI 0.00 to 4.73) and Eastern Europe (1.40%; 95% CI 0.38 to 4.96). History of STIs, torture, blood transfusion and African origin were identified as factors associated with increased prevalence of STIs/BBVs.
Conclusions This study underscores the regional disparities in the burden of STIs/BBVs among RAS. These findings highlight the importance of targeted screening for STIs/BBVs based on the country/region of origin and individual risk factors, and implementation of mitigation measures (eg, improving healthcare access and raising awareness) tailored to their unique needs. Such measures are crucial for reducing the impact of STIs/BBVs in both RAS and host countries.
PROSPERO registration number CRD42024546750.
- HIV
- hepatitis
- syphilis
Data availability statement
All data relevant to the study are included in the article or uploaded as supplementary information.
Statistics from Altmetric.com
Footnotes
Handling editor Carmen Lisboa
X @jdean4atUQ
Contributors WS: conceptualisation, methodology, investigation (screened articles, extracted data and quality appraisal), formal analysis, visualisation and writing—original draft and editing. BMM: investigation (screened articles, data extraction and quality appraisal), writing—review and editing. JAD: supervision, writing—review and editing. DM: writing—review and editing. KK: writing—review and editing. CL: supervision, writing—review and editing. LF-K: conceptualisation, supervision, writing—review and editing.
Funding WS was granted the University of Queensland Research Training Stipend Scholarship to pursue his PhD. CL was supported by an NHMRC Investigator Grant (APP1193826).
Map disclaimer The inclusion of any map (including the depiction of any boundaries therein), or of any geographic or locational reference, does not imply the expression of any opinion whatsoever on the part of BMJ concerning the legal status of any country, territory, jurisdiction or area or of its authorities. Any such expression remains solely that of the relevant source and is not endorsed by BMJ. Maps are provided without any warranty of any kind, either express or implied.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.